Monocyte dysfunction in decompensated cirrhosis is mediated by the prostaglandin E2-EP4 pathway

Area of Science:

• Hepatology
• Immunology
• Pharmacology

Background:

• Advanced liver disease, specifically decompensated cirrhosis, is associated with high infection rates and mortality.
• Monocyte dysfunction is a key factor contributing to increased susceptibility to infection in these patients.
• Elevated prostaglandin E2 (PGE2) is identified as a mediator of this monocyte dysfunction.

Purpose of the Study:

• To investigate the role of PGE2 signaling in monocyte dysfunction in patients with decompensated cirrhosis.
• To compare PGE2 levels and monocyte function in outpatients with ascites versus hospitalized patients with acute decompensation.
• To identify potential therapeutic targets for improving monocyte function and preventing infection.

Main Methods:

• Assayed plasma PGE2 and lipopolysaccharide (LPS) levels.
• Performed quantitative real-time PCR on monocytes and assessed peripheral blood monocyte function (HLA-DR, TNF-α, IL-6 production).
• Investigated PGE2 receptor (EP4) involvement and the effect of PGE2 antagonists using flow cytometry and cytokine analysis.

Main Results:

• Hepatic and monocytic production of PGE2 contributes to elevated plasma levels in decompensated cirrhosis.
• Monocyte numbers increased, while individual monocyte function (HLA-DR expression, cytokine production) decreased with disease severity.
• PGE2-mediated monocyte dysfunction occurs via the EP4 receptor, worsening in hospitalized patients.

Conclusions:

• PGE2, acting through its EP4 receptor, mediates monocyte dysfunction in decompensated cirrhosis.
• Monocyte dysfunction is more severe in hospitalized patients compared to outpatients with ascites.
• Targeting the EP4 receptor presents a potential therapeutic strategy to improve monocyte function, prevent infection, and reduce hospitalizations.